Chemspace is an online marketplace for small molecules with billions of compounds to search and buy. Chemspace offers its customers the largest catalog of commercially available chemicals. The catalog includes over 400K in-stock building blocks and reagents, over 6M in-stock screening compounds, and billions of make-on-demand analogs of the in-stock items. We collaborate with over 80 suppliers located worldwide to deliver diverse chemistry offer to our customers. Our experienced sourcing team helps Chemspace customers find off-catalog items including those that require custom synthesis. The platform with a fast chemical search engine allows its users to search by exact match, similarity, and substructure in billions of items. There are different software solutions for integration available, including API, and a punchout site. Our logistics hubs in the US and the EU support fast delivery, customs clearance, and consolidation. Chemspace also provides a sample formatting service via its partners to deliver compounds in preferred plates or vials.

Enantis is a biotech SME based in the Czech Republic. Our main expertise lies in protein and enzyme engineering. We focus on our own pipeline of products as well as we provide confidential contract research services to other subjects.

Enantis uses a highly innovative approach of in silico predictions of beneficial mutations in the protein sequence. These mutations are able to improve molecular stability, activity or selectivity without any extra additives. For this, we use our proprietary software and long-term expertise. The sequence alterations are predicted by our unique protein engineering platform (energy and evolution predictions coupled with rational design).

One of our products, hyperstable FGF2 has been engineered to be 50x more stable than its native counterpart. Similar commercially attractive molecules are being developed at Enantis. For our clients, we are able to improve molecules for industrial, pharma or research purposes, as our engineering platform is highly universal.  

Iktos is an innovative company specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically medicinal chemistry and new drug design. The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D. Iktos technology is built upon the latest developments in deep learning algorithms, for de novo design and AI-driven synthesis planning. Founded in 2016, we already have a portfolio of 50 plus real world projects either completed or ongoing. Our customizable technology offers multiple proprietary algorithms to clients, including large/medium pharma, biotech companies and research institutes globally.

LAXAI is a fully integrated contract research and development organization that delivers solutions in drug discovery, chemical process development, and GMP manufacturing for innovator pharmaceutical, Biotech, and animal health companies globally. Over the years, our focus has been on providing highly efficient scientific solutions, which has enabled us to partner on more than 20 integrated drug discovery programs and multiple medicinal chemistry-focused FTE collaborations. As a result, we have delivered clinical candidates and technology platforms in Oncology, Rheumatoid Arthritis, and Antibacterial respectively. Further, owing to our strength in chemistry and our experience in solving complex problems, we have been engaged in a number of chemical process development and GMP manufacturing projects by innovator pharmaceutical companies. This experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs, and custom-manufactured advanced intermediates and fine chemicals.

NovAliX is a drug discovery focused CRO, highly proficient in chemistry and biophysics, with several unique technologies.

The company has set up one of the world’s most comprehensive biophysics platforms, from screening to identification and detailed characterization of drug-target interactions using protein X-ray crystallography, native MS, NMR, SPR and cryo-EM.

Our award-winning chemistry teams have delivered on numerous projects in medicinal chemistry, process research and discovery chemistry.

NovAliX’ innovative, cost-effective, collaborative and co-located research programs involve dedicated teams of scientists working throughout Europe in its partners’ laboratories. Close proximity fosters the seamless transfer of knowledge in both directions and speeds up the research process.

NovAliX, founded in 2002, is based in Strasbourg, France, in the heart of the BioValley Upper Rhine region, France.

At Pivot Park Screening Centre we’re here help you accelerate early drug discovery. To achieve this, we offer bespoke services in the fields of assay development, lab automation, Ultra-High Throughput Screening (uHTS), and biological profiling. We foster a collaborative, ‘open culture’ with a clear focus on excellence. Attracting passionate, talented, ‘high achievers’ from the international scientific community. Which is why we are continuously expanding our knowledge and experience, to the benefit of our colleagues, clients, and partners. Pivot Park Screening Centre (PPSC) was established in 2012 as a spin-off from Organon/MSD and includes state-of-the-art robotic systems, instrumentation for biological profiling, and a collection of 300,000 high-quality drug-like compounds. Our team has more than two decades of proven experience and we continue to grow. Historically, we emerged from the former Organon / MSD’s screening centre, developing into a central screening site within the European Lead Factory.

Sai Life Sciences is a pure-play, full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with global innovator biotech and pharma companies to accelerate the discovery, development, and manufacture of complex small molecules. Over the past two decades, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, in addition to several small and mid-sized pharma & biotech companies. As one of India’s fastest growing CDMOs, the company is investing over the US $ 150 Mn in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

Syncrosome is a preclinical CRO dedicated to in vivo efficacy studies. More than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in vivo efficacy studies to offer better predictability and anticipate clinical results. Syncrosome offer relevant disease models, cutting-edge techniques, specific biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. We have developed and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

sa-FORD is a contract research organization that has established its name as a leading service provider for toxicology research in India. It is located at Taloja in Navi Mumbai and was established in 2008 by a team of German and Indian scientists with a view to provide regulatory research solutions to clients from the pharmaceutical, agrochemical and chemical industry. In 2011, the lab was awarded certification for OECD-GLP (Good Laboratory Practices) by the National GLP-Compliance Monitoring Authority of India, which operates under the aegis of the Ministry of Science and Technology, Government of India. Currently, sa-FORD mainly takes up non-clinical research projects and offers a range of services in the areas of Chemistry, Toxicology and Pathology under the scope of GLP. Standing true to its vision, it has already worked for clients from the Americas, Europe, Australia, South-East and Eastern Asia and of-course, the Indian sub-continent. 

One of the biggest vertically integrated Cannabis Companies in Israel. The Full Control of the Value Chain, from Cultivation to Distribution, enables us to Meet the Highest Quality Standards and Supply Market’s Demand. We take Pride in our Cutting-edge Research and Development Capabilities and aim to constantly Innovate to offer the next Generation of Medical Cannabis Products. We Provide end to end Solution, Combining Science and Nature to Create unique Quality Flowers and Extracts.